HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MEDP
Medpace Holdings, Inc.
MEDP's fundamentals are strong: revenue grew 20% and it turned 24% of its revenue into free cash flow. At 36x earnings, it's trading in line with its usual 34x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MEDP Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
MEDP's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MEDP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $493 | -25% |
| Fair | 34x | $611 | -7% |
| Forward | 34x | $657 | — |
| Current | 36x | $657 | — |
| Expensive | 42x | $748 | +14% |
Historical ranges are pointers, not guarantees.
MEDP's PE is in its fair range at 36x. If earnings grow as analysts expect, today's price would be 34x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MEDP Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
MEDP has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MEDP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $19.28 | +7% |
| Q3 2026 | $18.02 | +26% |
| Q2 2026 | $17.04 | +27% |
| Q1 2026 | $15.89 | +21% |
| Q4 2025 | $15.28 | +21% |
| Q3 2025 | $14.30 | +25% |
| Q2 2025 | $13.45 | +27% |
| Q1 2025 | $13.10 | +34% |
| Q4 2024 | $12.63 | +42% |
MEDP has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MEDP on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MEDP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $716M | +8.5% |
| Q2 2026 | $707.3M | +17% |
| Q1 2026 | $706.6M | +27% |
| Q4 2025 | $708.5M | +32% |
| Q3 2025 | $659.9M | +24% |
| Q2 2025 | $603.3M | +14% |
| Q1 2025 | $558.6M | +9.3% |
| Q4 2024 | $536.6M | +7.7% |
MEDP's revenue has grown year over year every quarter since late 2020: $716M last quarter, up 8.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +1.6 points |
| Q2 2026 | 21% | -0.2 points |
| Q1 2026 | 20% | -0.3 points |
| Q4 2025 | 22% | -1.7 points |
| Q3 2025 | 21% | +0.4 points |
| Q2 2025 | 21% | +1 points |
| Q1 2025 | 20% | 0 points |
| Q4 2024 | 23% | +5.9 points |
MEDP has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MEDP on cash flow, with more consistent year-over-year improvement.
MEDP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $196.4M | -17% |
| Q2 2026 | $138.1M | -3% |
| Q1 2026 | $145M | +25% |
| Q4 2025 | $188.1M | +2.8% |
| Q3 2025 | $235.5M | +70% |
| Q2 2025 | $142.4M | +38% |
| Q1 2025 | $115.8M | -21% |
| Q4 2024 | $183M | +25% |
MEDP's free cash flow has been positive every quarter for seven years: $668M over the past year, down 1.4% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MEDP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MEDP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -182K shares |
| 1 year | -1.5% | -445K shares |
| 3 years | -11% | -3.4M shares |
| 5 years | -24% | -9.1M shares |
| Available history | -24% | -9.2M shares |
MEDP has 28M diluted shares, down 1.5% from a year ago, with $295M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $294.8M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $4.6M |
| Q2 2025 | $540.9M |
| Q1 2025 | $371.9M |
| Q4 2024 | $169.9M |
MEDP spent $295M buying back its own shares over the past year, down 73% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MEDP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.8x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
MEDP has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MEDP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.0 | Neutral |
| Stochastic | 68.8 | Neutral |
MEDP's weekly RSI is 65 (neutral) and its Stochastic is 69 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MEDP PE vs Healthcare Sector
| Metric | MEDP | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 26x | 41% above |
| PE % | 65 | 29 | 36 pts above |
MEDP is trading at 36x earnings, a 41% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MEDP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $635.0 | 3.4% above |
| 20 week MA | $603.7 | 8.8% above |
| 50 week MA | $538.6 | 22% above |
| 100 week MA | $466.3 | 41% above |
| 200 week MA | $384.2 | 71% above |
MEDP has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MEDP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $83.7 | $139.1 | +66% |
| 2021 | $139.1 | $223.4 | +61% |
| 2022 | $223.4 | $212.7 | -4.8% |
| 2023 | $212.7 | $306.5 | +44% |
| 2024 | $306.5 | $341.1 | +11% |
| 2025 | $341.1 | $567.6 | +66% |
| 2026 YTD | $567.6 | $656.8 | +16% |
MEDP has the edge over HIMS on returns for 2026, with the stronger performance.